ProVerum’s ProVee system makes commercial debut in U.S with first BPH treatment procedures

IRELAND—ProVerum Limited, an Ireland-based medical device company specializing in innovative treatments for benign prostatic hyperplasia (BPH), has reached a significant milestone with the completion of its first commercial procedures using the ProVee System in the United States.

The achievement represents a crucial advancement in the company’s clinical and commercial expansion across the American market, bringing a new treatment option to millions of men struggling with BPH-related symptoms.

The ProVee System represents a next-generation prostatic urethral stent designed to address the challenges of BPH through a gentler, less invasive approach.

The device works by carefully opening the obstructed prostate, providing relief from lower urinary tract symptoms that significantly impact patients’ daily lives.

Unlike traditional BPH interventions, the ProVee System operates without cutting, burning, tearing, or piercing prostatic tissue, which potentially offers patients an improved safety profile and accelerated recovery times compared to conventional surgical methods.

Experienced urologists at multiple locations across the United States performed the initial commercial procedures, demonstrating strong physician interest in minimally invasive BPH management solutions.

These pioneering cases mark the first real-world patient use of the ProVee System in the country and provide invaluable insights as ProVerum continues to expand clinical adoption and enhance physician training programs nationwide.

The early adopters include highly respected, innovation-focused urologists from prominent practices across the nation.

Dr. Tyler McClintock and Dr. Michael Trotter from Midtown Urology Associates, Dr. Brian Mazzarella from Urology Austin, Dr. Ricardo Gonzalez from Houston Methodist, and Dr. Sijo Parekattil from Avant Concierge Urology led the initial wave of procedures.

Additional pioneering physicians include Dr. Raviender Bukkapatnam from Florida Urology Partners, Dr. Sheldon Freedman from Freedman Urology, and Dr. Ning Wu from Comprehensive Urologic Care.

Paul Bateman, Chief Executive Officer of ProVerum, expressed enthusiasm about the company’s progress following recent FDA approval.

He emphasized that the company now stands well-positioned to help men alleviate urinary symptoms caused by BPH through the innovative ProVee procedure.

Bateman noted that successfully completing the first commercial procedures in the United States represents a significant milestone that reflects the growing demand among both physicians and patients for minimally invasive BPH treatment options.

BPH stands as the most common reason men seek urological care, with more than 12 million men in the United States actively receiving management for the condition.

Patients experience a range of disruptive symptoms, including frequent or urgent urination, increased nighttime bathroom visits, weakened urine streams, and incomplete bladder emptying.

Without appropriate treatment, these symptoms typically worsen over time and substantially diminish quality of life, affecting sleep patterns, work productivity, and overall well-being.